Children With Diabetes and At Least One Non-Autoimmune Feature Should Be Considered for Monogenic Diabetes Testing - Takeaways - MDSpire

Children With Diabetes and At Least One Non-Autoimmune Feature Should Be Considered for Monogenic Diabetes Testing

  • By

  • Rebecca Myers

  • Melek Yildiz

  • Mehmet Nuri Ozbek

  • Jaida Manzoor

  • Mohsina Ibrahim

  • Chittaranjan Yajnik

  • Muge Atar

  • Zeynep Şiklar

  • Sezer Acar

  • Evgenia Globa

  • Omneya Magdy Omar

  • Huseyin Demirbilek

  • Samar Hassan

  • Korcan Demir

  • Misbah Hanif

  • Tulay Guran

  • Nihal Hatipoglu

  • Cemil Koçyiğit

  • Kevin Colclough

  • Jayne Houghton

  • Andrew Hattersley

  • Rachel Van Heugten

  • Kashyap Patel

  • Monogenic Diabetes Consortium

  • Y Abdelmeguid

  • S Abourazzak

  • A Annamalai

  • E Bhowmik

  • G Catli

  • S Chapman

  • H Eideh

  • V Jain

  • T Kontbay

  • V Mulliqi Kotori

  • G Supriya

  • S Musa

  • M Šandrk Beslać

  • M Sharaf

  • J Yong

  • G Yesiltepe Mutlu

  • R Yildirim

  • O Yilmaz

  • M Berberoglu

  • T Akcay

  • C Datar

  • S Dhadge

  • K Jog

  • August 1, 2025

  • 0 min

Share

  • 1

    Monogenic diabetes testing should be considered for all children with diabetes and at least one non-autoimmune extra-pancreatic feature.

  • 2

    In a study of 183 children, 33% were diagnosed with monogenic diabetes, predominantly with recessive etiologies.

  • 3

    Common genetic variants identified included WFS1, SLC19A2, and SLC29A3, with high parental consanguinity reported in monogenic cases.

  • 4

    Children with low type 1 diabetes genetic risk scores and negative autoantibodies were more likely to have a monogenic cause.

  • 5

    The study highlights the need for targeted genetic testing to improve diagnosis and management of syndromic diabetes.

Original Source(s)

Children With Diabetes and At Least One Non-Autoimmune Feature Should Be Considered for Monogenic Diabetes Testing

  • by Rebecca Myers, Melek Yildiz, Mehmet Nuri Ozbek, Jaida Manzoor, Mohsina Ibrahim, Chittaranjan Yajnik, Muge Atar, Zeynep Şiklar, Sezer Acar, Evgenia Globa, Omneya Magdy Omar, Huseyin Demirbilek, Samar Hassan, Korcan Demir, Misbah Hanif, Tulay Guran, Nihal Hatipoglu, Cemil Koçyiğit, Kevin Colclough, Jayne Houghton, Andrew Hattersley, Rachel Van Heugten, Kashyap Patel, Monogenic Diabetes Consortium, Y Abdelmeguid, S Abourazzak, A Annamalai, E Bhowmik, G Catli, S Chapman, H Eideh, V Jain, T Kontbay, V Mulliqi Kotori, G Supriya, S Musa, M Šandrk Beslać, M Sharaf, J Yong, G Yesiltepe Mutlu, R Yildirim, O Yilmaz, M Berberoglu, T Akcay, C Datar, S Dhadge, K Jog

  • August 1, 2025

Related Content

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

What RVO May Reveal About Systemic Health

TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy